X4 PHARMACEUTICALS, INC Repayments of Long-Term Debt
X4 PHARMACEUTICALS, INC (XFOR) reported Repayments of Long-Term Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-03-17
- X4 PHARMACEUTICALS, INC repayments of long-term debt for the quarter ending 2020-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC repayments of long-term debt for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC repayments of long-term debt for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC repayments of long-term debt for the quarter ending 2019-09-30 was $6.45M, a 1190.80% increase year-over-year.
- X4 PHARMACEUTICALS, INC repayments of long-term debt for fiscal 2025 was $0.00.
- X4 PHARMACEUTICALS, INC repayments of long-term debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- X4 PHARMACEUTICALS, INC repayments of long-term debt for fiscal 2023 was $2.06M, a 159.62% increase from fiscal 2022.
- X4 PHARMACEUTICALS, INC repayments of long-term debt for fiscal 2022 was $795.00K.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 3 month as first filed | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 6 month as first filed | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 9 month as first filed | Repayments of Long-term Debt 12 month | Repayments of Long-term Debt 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-17 | |||||||
| 2024-12-31 | $0.00 10-K · filed 2026-03-17 | |||||||
| 2023-12-31 | $2.06M 10-K · filed 2026-03-17 | |||||||
| 2022-12-31 | $795.00K 10-K · filed 2025-03-26 | |||||||
| 2021-12-31 | $0.00 10-K · filed 2024-03-21 | |||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $0.00 derived: sum of 2 quarters · filed 2023-03-21 | $0.00 10-K · filed 2023-03-21 | |||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||||||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-04 | |||||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $6.45M derived: sum of 2 quarters · filed 2022-03-17 | $9.37M 10-K · filed 2022-03-17 | |||||
| 2019-09-30 | $6.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $9.37M 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | $2.91M 10-Q · filed 2020-08-04 | |||||||
| 2018-12-31 | $4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $5.38M derived: sum of 2 quarters · filed 2021-03-19 | $5.88M derived: sum of 3 quarters · filed 2021-03-19 | $6.38M 10-K · filed 2021-03-19 | $4.67M 10-K · filed 2019-03-11 | |||
| 2018-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $1.00M derived: sum of 2 quarters · filed 2019-11-07 | $1.50M 10-Q · filed 2019-11-07 | $1.75M 10-Q · filed 2018-11-09 | -$250.00K derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2018-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $1.00M 10-Q · filed 2019-08-07 | $1.17M 10-Q · filed 2018-08-13 | -$750.00K derived: sum of 3 quarters · filed 2020-03-12 | -$165.00K derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2018-03-31 | $500.00K 10-Q · filed 2019-05-15 | $583.00K 10-Q · filed 2018-05-10 | -$1.25M derived: sum of 2 quarters · filed 2020-03-12 | -$665.00K derived: sum of 3 quarters · filed 2020-03-12 | -$82.00K derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | -$1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$1.17M derived: sum of 2 quarters · filed 2020-03-12 | -$582.00K derived: sum of 3 quarters · filed 2020-03-12 | $0.00 10-K · filed 2020-03-12 | $2.33M 10-K · filed 2019-03-11 | |||
| 2017-09-30 | $585.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $1.17M derived: sum of 2 quarters · filed 2018-11-09 | $1.75M 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | $583.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $1.17M 10-Q · filed 2018-08-13 | ||||||
| 2017-03-31 | $582.00K 10-Q · filed 2018-05-10 | |||||||
| 2016-12-31 | $250.00K 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |